A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to demonstrate the superiority in progression-free survival
(PFS) of dinaciclib compared to ofatumumab in chronic lymphocytic leukemia (CLL) participants
with del 17p or in the overall population who are refractory to either fludarabine treatment
or chemoimmunotherapy.